SG10202102467RA - Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond - Google Patents
Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bondInfo
- Publication number
- SG10202102467RA SG10202102467RA SG10202102467RA SG10202102467RA SG10202102467RA SG 10202102467R A SG10202102467R A SG 10202102467RA SG 10202102467R A SG10202102467R A SG 10202102467RA SG 10202102467R A SG10202102467R A SG 10202102467RA SG 10202102467R A SG10202102467R A SG 10202102467RA
- Authority
- SG
- Singapore
- Prior art keywords
- conjugating
- protein
- agent
- methods
- thiol moiety
- Prior art date
Links
- 230000001268 conjugating effect Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 125000003396 thiol group Chemical group [H]S* 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462028679P | 2014-07-24 | 2014-07-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202102467RA true SG10202102467RA (en) | 2021-04-29 |
Family
ID=55163580
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202102467RA SG10202102467RA (en) | 2014-07-24 | 2015-07-17 | Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond |
SG11201700365TA SG11201700365TA (en) | 2014-07-24 | 2015-07-17 | Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201700365TA SG11201700365TA (en) | 2014-07-24 | 2015-07-17 | Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond |
Country Status (15)
Country | Link |
---|---|
US (2) | US11370838B2 (en) |
EP (1) | EP3172219A4 (en) |
JP (3) | JP6956630B2 (en) |
KR (1) | KR102463267B1 (en) |
CN (1) | CN106536540A (en) |
AR (1) | AR101304A1 (en) |
AU (2) | AU2015294389B2 (en) |
BR (1) | BR112017001403A2 (en) |
CA (1) | CA2955007C (en) |
IL (1) | IL250148B2 (en) |
MX (2) | MX2017001022A (en) |
MY (1) | MY198629A (en) |
RU (2) | RU2744978C2 (en) |
SG (2) | SG10202102467RA (en) |
WO (1) | WO2016014360A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10202102467RA (en) * | 2014-07-24 | 2021-04-29 | Genentech Inc | Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond |
BR112019015044A2 (en) * | 2017-02-08 | 2020-03-10 | Pfizer Inc. | LARGE-SCALE PRODUCTION PROCESS FOR HARVESTED AND UNLARGED ANTIBODY CYSTEINS AND THEIR USE IN THE CONJUGATION OF THERAPEUTIC PROTEINS |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS5896026A (en) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | Novel urokinase derivative, its preparation and thrombolytic agent containing the same |
US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
JP2665353B2 (en) * | 1988-09-10 | 1997-10-22 | 住商ファーマインターナショナル株式会社 | Methods for producing bispecific antibodies |
JPH0278699A (en) | 1988-09-12 | 1990-03-19 | Green Cross Corp:The | Benzoylurea compound-albumin complex |
JPH02218700A (en) * | 1989-02-17 | 1990-08-31 | Nippon Kayaku Co Ltd | Dispecific antibody and adoptive immunity using the same antibody |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
ZA955789B (en) | 1994-07-15 | 1996-03-11 | Novo Nordisk As | A method of converting a hydrophobic derivative of a polypeptide into the native form |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
JPH11124395A (en) | 1997-10-16 | 1999-05-11 | Seiwa Kasei Kk | Peptide containing cysteine introduced thereinto and its production |
SE9802454D0 (en) | 1998-07-08 | 1998-07-08 | Pharmacia & Upjohn Ab | Production of peptides |
WO2000071716A2 (en) | 1999-05-20 | 2000-11-30 | Scios Inc. | Vascular endothelial growth factor dimers |
MXPA03003867A (en) | 2000-10-31 | 2004-10-15 | Univ Colorado Regents | Improved methods for protein refolding. |
US7737260B2 (en) * | 2003-11-13 | 2010-06-15 | Hanmi Pharm. Co., Ltd | Protein complex using an immunoglobulin fragment and method for the preparation thereof |
WO2004010957A2 (en) | 2002-07-31 | 2004-02-05 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US20040048315A1 (en) | 2002-08-28 | 2004-03-11 | Pharmacia Corporation | Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof |
US7662387B2 (en) * | 2003-02-20 | 2010-02-16 | Seattle Genetics | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
WO2005084390A2 (en) * | 2004-03-02 | 2005-09-15 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
KR101200133B1 (en) * | 2004-06-01 | 2012-11-13 | 제넨테크, 인크. | Antibody drug conjugates and methods |
US20090131311A1 (en) * | 2004-12-29 | 2009-05-21 | Novo Nordisk Healthcare Ag | Method for Preventing Formation of Trisulfide Derivatives of Polypeptides |
BRPI0711249A2 (en) * | 2006-05-30 | 2012-03-13 | Genentech, Inc. | ANTIBODIES, POLYNUCLEOTIDES, VECTORS, HOST CELLS, METHODS FOR MANUFACTURING AN ANTIBODY, TO DETECTION THE PRESENCE OF CD2 IN A BIOLOGICAL SAMPLE, TO TREAT A PROLIFERATIVE B-CELL DIFFERENCE, CELL FOR PROLIBA CULAR, CELL FOR CIBLES ANTI-BODY DRUG CONJUGATE. IMMUNOCONJUGATES, PHARMACEUTICAL COMPOSITIONS, PHARMACEUTICAL FORMULATIONS, ANTIBODY-DRUG CONJUGATE, ANTIBODY-DRUG CONJUGATE COMPOUNDS, B-CELL DETECTION TEST AND MANUFACTURING ARTICLE |
US20080220448A1 (en) | 2006-09-01 | 2008-09-11 | Blincko Stuart J | Antigenic protein conjugates and process for preparing same |
JP5394246B2 (en) | 2007-03-30 | 2014-01-22 | ジェネンテック, インコーポレイテッド | Antibodies and immunoconjugates and methods for their use |
AU2008251608B2 (en) * | 2007-05-08 | 2014-03-27 | Genentech, Inc. | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
WO2009012256A1 (en) | 2007-07-16 | 2009-01-22 | Genentech, Inc. | Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
ES2381788T3 (en) | 2007-07-16 | 2012-05-31 | Genentech, Inc. | Anti-CD79b and immunoconjugate antibodies and methods of use |
CA2713773C (en) * | 2008-01-31 | 2017-05-30 | Georgia-Pacific Chemicals Llc | Oxidized and maleated derivative composition |
IL287292B (en) | 2008-01-31 | 2022-09-01 | Genentech Inc | Cycteine engineering anti-cd79b antibodies and antibody-drug conjugates |
EP2483289B1 (en) * | 2009-10-02 | 2019-03-20 | Biogen MA Inc. | Methods of preventing and removing trisulfide bonds |
PT2542576T (en) * | 2010-03-02 | 2016-07-14 | Seattle Genetics Inc | Methods for screening antibodies |
SG190082A1 (en) * | 2010-11-05 | 2013-06-28 | Covx Technologies Ireland Ltd | Anti-diabetic compounds |
WO2012158551A1 (en) * | 2011-05-13 | 2012-11-22 | Biogen Idec Ma Inc. | Methods of preventing and removing trisulfide bonds |
AU2012328322A1 (en) * | 2011-10-27 | 2014-06-12 | Genmab A/S | Production of heterodimeric proteins |
EP3539982A3 (en) * | 2011-12-23 | 2020-01-15 | Pfizer Inc | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
EP2844300B1 (en) * | 2012-05-01 | 2018-10-17 | Genentech, Inc. | Anti-pmel17 antibodies and immunoconjugates |
KR20150023027A (en) * | 2012-06-19 | 2015-03-04 | 폴리테릭스 리미티드 | Novel Process for Preparation of Antibody Conjugates and Novel Antibody Conjugates |
SG10202102467RA (en) * | 2014-07-24 | 2021-04-29 | Genentech Inc | Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond |
-
2015
- 2015-07-17 SG SG10202102467RA patent/SG10202102467RA/en unknown
- 2015-07-17 AU AU2015294389A patent/AU2015294389B2/en not_active Expired - Fee Related
- 2015-07-17 CA CA2955007A patent/CA2955007C/en active Active
- 2015-07-17 KR KR1020177003843A patent/KR102463267B1/en active IP Right Grant
- 2015-07-17 CN CN201580041071.9A patent/CN106536540A/en active Pending
- 2015-07-17 EP EP15824358.4A patent/EP3172219A4/en active Pending
- 2015-07-17 RU RU2017105428A patent/RU2744978C2/en active
- 2015-07-17 BR BR112017001403A patent/BR112017001403A2/en not_active Application Discontinuation
- 2015-07-17 RU RU2021106673A patent/RU2021106673A/en unknown
- 2015-07-17 WO PCT/US2015/040931 patent/WO2016014360A1/en active Application Filing
- 2015-07-17 SG SG11201700365TA patent/SG11201700365TA/en unknown
- 2015-07-17 MY MYPI2017000109A patent/MY198629A/en unknown
- 2015-07-17 MX MX2017001022A patent/MX2017001022A/en unknown
- 2015-07-17 JP JP2017503957A patent/JP6956630B2/en active Active
- 2015-07-24 AR ARP150102358A patent/AR101304A1/en unknown
-
2017
- 2017-01-16 IL IL250148A patent/IL250148B2/en unknown
- 2017-01-20 MX MX2022012589A patent/MX2022012589A/en unknown
- 2017-01-24 US US15/414,330 patent/US11370838B2/en active Active
-
2020
- 2020-12-01 JP JP2020199681A patent/JP7219256B2/en active Active
-
2021
- 2021-07-27 AU AU2021209196A patent/AU2021209196B2/en active Active
-
2022
- 2022-05-24 US US17/752,631 patent/US20220372141A1/en active Pending
-
2023
- 2023-01-26 JP JP2023010054A patent/JP2023052645A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL261188A (en) | Antibodies to tigit | |
IL290457A (en) | Antibodies and conjugates thereof | |
IL254108A0 (en) | Amatoxin-antibody conjugates | |
IL250819A0 (en) | Pyrrolobenzodiazepines and antibody disulfide conjugates thereof | |
ZA201607385B (en) | Anti-ptk7 antibody-drug conjugates | |
DK3119885T3 (en) | Antibody-fynomer conjugates | |
ZA201701337B (en) | Conjugates and conjugating reagents | |
EP3129357C0 (en) | Affinity medicant conjugates | |
DK3148591T3 (en) | Nanoparticle-drug conjugates | |
GB201513607D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
IL253549B (en) | Antibody-urease conjugates for therapeutic purposes | |
GB201504694D0 (en) | Covalent conjugates | |
IL250148A0 (en) | Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond | |
HK1257229A1 (en) | Cck2r-drug conjugates | |
GB2554027B (en) | Glue compositions and methods | |
GB201620828D0 (en) | Compositions of antibody construct-agonist conjugates and methods thereof | |
GB201518839D0 (en) | Conjugates | |
GB201513605D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
FR3022492B1 (en) | PNEUMATIC IN TWO PARTS SUITABLE FOR RECHAPING | |
GB201418986D0 (en) | Novel conjugates and novel conjugating reagents | |
UA29483S (en) | BALL JOINT FINGER | |
UA29250S (en) | BALL JOINT FINGER | |
UA26904S (en) | BALL JOINT FINGER | |
UA29116S (en) | BALL JOINT FINGER | |
UA29219S (en) | BALL JOINT FINGER |